Abstract:7 Objectives: Negative allosteric modulation of metabotropic glutamate receptor 2 (mGlu2) represents a novel specific and selective approach for treating brain disorders. Positron emission tomography (PET) imaging of mGlu2 would facilitate disease diagnosis and negative allosteric modulators (NAMs) discovery. However, few efforts have been disclosed to visualize mGlu2in vivo, indicating an unmet and urgent clinical demand. Herein we report the proof-of-concept development of PET tracers derived from NAMs for successfully imaging of mGlu2. Methods: A library seven mGlu2 NAMs 1a-1g were synthesized and subjected to the investigation of pharmacological and physicochemical properties. As a result, 1a and 1b showed excellent potency and selectivity, and then radiolabeled with 11C. The specificities of both PET tracers [11C]1a and [11C]1b were validated by in vitro autoradiography (ARG) with rat brain slices. Dynamic PET imaging were performed on normal Sprague-Dawley (SD) rats to assess the capability for brain penetration and in vivo specificity by the simplified reference tissue model (SRTM) with the pons as the reference region. Whole body biodistribution and metabolite studies were conducted in rodents to evaluate the pharmacokinetic properties of [11C]1b. Results: All of the novel compounds were synthesized in five steps with 14-20% overall yields.1a and 1b showed good binding potency (IC50 to mGlu2 30 μM), together with reasonable lipophilicity and tPSA. 11C radiolabeling were conducted within 40 min on GE TracerLab FXC, and radiochemical yields were 36.6 ± 7.3% (n = 7, [11C]1a) and 6.53 ± 1.5% (n = 10, [11C]1b) respectively, with high radiochemical purities and molar activities. ARG results showed that [11C]1b was much more specific to mGlu2 with highest radioactivity accumulated in the striatum and cerebral cortex, followed by hippocampus and cerebellum. The heterogeneous distribution was diminished by pre-incubation with the corresponding standard compounds or QCA. The non-displaceable binding potential (BPND) of [11C]1bwere calculated by PET, and the highest values were observed in striatum and cingulate cortex (0.72), followed by cerebral cortex (0.42) and hippocampus (0.48), and the lowest BPND was identified in the cerebellum (0.12) under baseline conditions. The BPND values were decreased substantially by pretreatment with 1b (41-88% reduction, 1 mg/kg) or 1a (48-90% reduction, 3 mg/kg). Biodistribution studies of [11C]1b demonstrated that high brain uptake (ca. 3.6 %ID/g) was detected after 5 min post injection, which was consistent with PET imaging data. Several peripheral organs with high mGlu2 expression were also observed with high radioactivity accumulation. Notably, metabolite analysis suggested that [11C]1bshowed excellent in vivo stability in brain with more than 99% unchanged fraction at 20 min post injection. Conclusion: We have developed [11C]1b as a potent and promising PET tracer for neuroimaging of mGlu2. Translational PET imaging in nonhuman primates are on the way and will be reported in due course.

Mapping the Target Localization and Biodistribution of Non-Radiolabeled VMAT2 Ligands in rat Brain

Imaging of VMAT2 Binding Sites in the Brain by 18F-AV-133: the Effect of a Pseudo-Carrier

An Improved Radiosynthesis of [18F]AV-133: a PET Imaging Agent for Vesicular Monoamine Transporter 2.

Deuterated 18F-9-o-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A Vesicular Monoamine Transporter 2 (VMAT2) Imaging Agent.

X Deuterium Substituted D6fpdtbz (P17-059) As A New Vmat2 Imaging Agent

First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133)

Simultaneous Determination of Av-133 in Rat Brain and Blood by Microdialysis Combined with Lc-Ms/Ms

VMAT2 Imaging Agent, D6-[18F]FP-(+)-DTBZ: Improved Radiosynthesis, Purification by Solid-Phase Extraction and Characterization.

In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease

Brain Uptake of a Non-Radioactive Pseudo-Carrier and Its Effect on the Biodistribution of [(18)F]AV-133 in Mouse Brain.

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by 18F-FP-(+)-DTBZ PET

Kinetic Modeling of [18F]VAT, a Novel Radioligand for Positron Emission Tomography Imaging Vesicular Acetylcholine Transporter in Non‐human Primate Brain

Preclinical Evaluation Of Radiolabeled Negative Allosteric Modulators For Pet Imaging Of Metabotropic Glutamate Receptor 2

Exploration of Sulfur-Containing Analogues for Imaging Vesicular Acetylcholine Transporter in the Brain

Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity

Synthesis and biological evaluation of 18 F-labelled deuterated tropane derivatives as dopamine transporter probes

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

A Novel Carbon-11 PET Radiotracer for Imaging VAChT in the Brain

Synthesis and Evaluation of 2-Amino-dihydrotetrabenzine Derivatives As Probes for Imaging Vesicular Monoamine Transporter-2

PET Quantification of [18F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence

Synthesis and Evaluation of 2 Beta-(N-Halopyridylaminomethyl)-3 Beta-(4-Chlorophenyl)Tropanes As Potential Pet Ligands for Dopamine Transporter